Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 13.0-999.0,  Mycobacterium Avium-intracellulare Infection HIV Infections Concurrent Medication: Allowed Zidovudine (AZT) and didanosine (ddI). Dideoxycytidine (ddC), EPO, and other experimental therapies granted Treatment IND or Expanded Access status, with the exception of rifabutin Concurrent therapies (acute and maintenance) for opportunistic infections not specifically prohibited. Concurrent Treatment: Allowed Interferon-alfa. Patients must have the following HIV infections or diagnosis of AIDS as per CDC classification Mycobacterium avium isolated from blood Capability of signing an informed consent, or consent of guardian if < 18 years of age Ability and willingness to participate in all components of the study and receive all study therapies. Prior Medication: Allowed Interferon-alfa Single drug prophylaxis for Mycobacterium avium or M. tuberculosis within the previous 4 weeks  Co-existing Condition: Patients with the following symptoms or conditions are excluded: Treatment Phase Known or suspected allergy to any of the study medications. Severe hearing loss. Maintenance Phase Severe hearing loss. Hypersensitivity to macrolides. Intolerance to ethambutol and clofazimine. Concurrent Medication: Excluded Acute therapy for other opportunistic infections at time of study entry Nephrotoxic agents such as amphotericin B, intravenous vancomycin, or foscarnet during the first 4 weeks of study therapy without specific exemption from one of the protocol chairs. Antacids within 2 hours of ingestion of study drugs Immunomodulators (except interferon-alfa) and other antimycobacterial drugs (including quinolones and aminoglycosides) All experimental therapies (except ddI, ddC, and other experimental agents granted "Treatment IND" or "expanded access" status) will be prohibited (specific exemptions must be obtained from one of the protocol chairs). Patients with the following are excluded Known or suspected allergy to any of the study medications. Cannot take drugs orally Severe hearing loss, at the discretion of the investigator. Prior Medication: Excluded Antimycobacterial drugs (including azithromycin, clarithromycin, rifamycins, quinolones, and aminoglycosides) or immunomodulators (except interferon-alfa) within 4 weeks prior to entry, except single-drug prophylaxis specifically allowed. History of unreliable drug intake